Featured Research

from universities, journals, and other organizations

Not A "Morning-After" Pill, But UC Researchers Recommend Drugs To Prevent AIDS After Some Exposures

Date:
November 30, 1998
Source:
University Of California, Berkeley
Summary:
Immediate preventative treatment to ward off AIDS following possible exposure to HIV through sex or injection drug use is warranted under certain conditions, reports a University of California, Berkeley, researcher and her collaborators in the Nov. 25 Journal of the American Medical Association.

BERKELEY -- Immediate preventative treatment to ward off AIDS following possible exposure to HIV through sex or injection drug use is warranted under certain conditions, reports a University of California, Berkeley, researcher and her collaborators in the Nov. 25 Journal of the American Medical Association.

Such "prophylactic" treatment is already recommended by the Centers for Disease Control and Prevention, but only for doctors, nurses and other medical professionals after accidental exposure to infected body fluids on the job. In one study of health care workers exposed to HIV-infected blood, AZT use was associated with a 79 percent reduction in infection.

"We're applying this recommendation in certain situations to the much more frequent modes of HIV transmission, intravenous drug use and sexual transmission," said UC Berkeley Associate Field Research Supervisor Suellen Miller, PhD, CNM, a public health faculty member and co-author on the research paper, which appears in this week's issue of JAMA (11/25/98).

To substantiate these recommendations, the researchers present risk data in their paper and analyze the economics of treatment.

"A non-infected person who practices safer sex with their HIV-positive mate and is accidentally exposed through condom breakage should be considered for prophylactic treatment in the same way as health care workers suffering a needlestick injury," Miller said. "It is ethically mandatory that all persons who receive similar exposures should receive similar treatment."

Her co-authors from the University of California San Francisco are Dr. Peter Lurie and Margaret Chesney, PhD, both of the Center for AIDS Prevention Studies; Prof. Frederick Hecht, Department of Medicine, AIDS Program; and Dr. Bernard Lo, Program in Medical Ethics.

Unlike the one-shot "morning-after" pill for post-coital birth control, prophylactic AIDS prevention consists of a rigorous and expensive month-long course of drugs, often including protease inhibitors and AZT. It should be started not later than 72 hours after exposure.

"We are suggesting treatment scenarios similar to what survivors of sexual assault receive, who currently go to the emergency room and may be offered preventative treatment for other sexually transmitted diseases and even pregnancy, depending on risk factors," said Miller.

She said the biggest fear in the public health community - and probably the biggest objection that will be raised to the proposal - is the risk of developing resistance, both in the patient, should HIV be contracted, and in the community, where resistant strains could wreak havoc with present treatment strategies.

"These are potent drugs and they also require rigorous treatment regimens," she said.

Although there is no data on the effectiveness of prophylactic treatment in non-occupational settings, the authors provide epidemiological guidelines and clinical cases to assist clinicians in making the difficult decision of whether to treat.

"Although providing prophylactics to patients with appropriate non-occupational exposures to HIV is important, we need to monitor the impact on community levels of HIV risk behavior," said Lurie. "Our analysis shows that, even under assumptions favorable for treatment, a mere 10 percent increase in risk behaviors can obliterate any benefit that might come from treatment."

Side effects of the drugs vary from one individual to the next, but can include all problems associated with current treatments of AIDS patients using the protease/AZT drug combinations, such as nausea and fatigue.

Miller points out that not every exposure to HIV would call for prophylactic treatment. The JAMA paper recommends that physicians look at the prevalence of HIV in their community and the method of exposure before making the decision on treatment.

"This is recommended only for sporadic exposure. People who have an ongoing exposure," such as regular sex without the use of condoms, "really need to address that problem with primary prevention measures, such as abstinence, monogamy or consistent and correct condom use," she said.

The cost of prophylactic treatment could exceed $1,000 per exposure episode, with drug costs ranging from $500 to $1,000 and requisite physician and office visits running between $500 and $600.

The researchers are optimistic that insurance plans will cover such treatment in situations when the risk of infection is comparable to that experienced by medical personnel following HIV occupational exposure.


Story Source:

The above story is based on materials provided by University Of California, Berkeley. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, Berkeley. "Not A "Morning-After" Pill, But UC Researchers Recommend Drugs To Prevent AIDS After Some Exposures." ScienceDaily. ScienceDaily, 30 November 1998. <www.sciencedaily.com/releases/1998/11/981130050208.htm>.
University Of California, Berkeley. (1998, November 30). Not A "Morning-After" Pill, But UC Researchers Recommend Drugs To Prevent AIDS After Some Exposures. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1998/11/981130050208.htm
University Of California, Berkeley. "Not A "Morning-After" Pill, But UC Researchers Recommend Drugs To Prevent AIDS After Some Exposures." ScienceDaily. www.sciencedaily.com/releases/1998/11/981130050208.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins